Roche Cancer Vaccine Pact Could Net Immatics $1B-Plus

13-11-2013 Genetic Engineering NewsComments (0)

Biotechnologyimmatics biotechnologiesRoche

Roche will oversee clinical development and commercialization of all immunotherapies generated by immatics biotechnologies under a cancer vaccine and immunotherapy collaboration that could net the German clinical-stage biopharma more than $1 billion ...

Read more on Genetic Engineering News

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top